Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22000117 | 0.91 | ACLY (0.77) | ACLYMAPTSERPINE1KDM4EMEN1 | |
| SCHEMBL7034062 | 0.87 | ACLY (0.82) | ACLYMAPTSERPINE1KDM4ESUCNR1 | |
| SCHEMBL420185 | 0.85 | SERPINE1 (0.77) | MAPTSERPINE1KDM4ESMN1; SMN2SUCNR1 | |
| SCHEMBL7040693 | 0.84 | PPARG (0.60) | ACLYMAPTSERPINE1KDM4EMEN1 | |
| Lithium Ion SCHEMBL7146523 | 0.83 | ACLY (0.68) | ACLYMAPTSERPINE1KDM4EMEN1 | |
| SCHEMBL7038586 | 0.82 | PPARG (0.61) | ACLYSERPINE1KDM4ESMN1; SMN2SUCNR1 | |
| SCHEMBL22000164 | 0.82 | ACLY (0.79) | ACLYMAPTKDM4EMEN1KMT2A | |
| SCHEMBL7040635 | 0.82 | ACLY (0.61) | ACLYMAPTKDM4EKMT2ALMNA | |
| SCHEMBL22000122 | 0.81 | ACLY (0.80) | ACLYMAPTKDM4EMEN1KMT2A | |
| SCHEMBL2268029 | 0.80 | ACLY (1.00) | ACLYMAPTSERPINE1SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | ACLY 451/4885MAPT 4479/4885SERPINE1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.